Corrigendum to “SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT Pathway” [Neoplasia (2021) 23, 1037–1047]
Zhenzhen Luo,
Jing Wang,
Yue Zhu,
Xiao Sun,
Chenchen He,
Mengjiao Cai,
Jinlu Ma,
Yi Wang,
Suxia Han
Affiliations
Zhenzhen Luo
Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Jing Wang
Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Yue Zhu
Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Xiao Sun
Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Chenchen He
Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Mengjiao Cai
Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Jinlu Ma
Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Yi Wang
State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China; Corresponding author.
Suxia Han
Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Corresponding author.
